Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
FINAL ANALYSIS OF THE AHL201 RANDOMIZED PHASE III LYSA STUDY COMPARING AN EARLY PET DRIVEN TREATMENT DE-ESCALATION TO A NOT PET-MONITORED STRATEGY IN PATIENTS WITH ADVANCED STAGES HODGKIN LYMPHOMA
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): Olivier Casasnovas, Pauline Brice, Reda Bouabdallah, et. al Abstract: S110 Session topic: 17. Hodgkin lymphoma – Clinical...
PRETREATMENT VITAMIN D DEFICIENCY IS ASSOCIATED WITH LOWER PROGRESSION- -FREE AND OVERALL SURVIVAL IN PROSPECTIVELY TREATED HODGKIN LYMPHOMA
13 októbra, 2020 5:56 pm Leave your thoughtsAuthor(s): Sven Borchmann, Helen Görgen, Stephanie Sasse, et al. Abstract: S111 Session topic: 17. Hodgkin lymphoma – Clinical...
Nedostatok vitamínu D a znížené prežívanie pacientov s Hodgkinovým lymfómom
13 októbra, 2020 5:55 pm Leave your thoughtsAutori tejto práce testovali hypotézu, či znížená hladina vitamínu D znižuje prežívanie bez progresie (PFS) a celkové prežívanie (OS) pacientov s Hodgkinovým...
OUTCOMES BY NUMBER OF INDUCTION CYCLES WITH CPX-351 VERSUS 7+3 CHEMOTHERAPY IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (SAML)
13 októbra, 2020 5:55 pm Leave your thoughtsAuthor(s): Jorge E. Cortes, Bruno C. Medeiros, Geoffrey L. Uy, et al. Abstract: PF239 Session topic: 4. Acute...
COMBINATION OF IDARUBICIN, CYTARABINE AND CLADRIBINE AS INDUCTION REGIMEN FOR UNTREATED ADULT AML AGED 60 OR YOUNGER: A PHASE III RANDOMIZED CLINICAL TRIAL
13 októbra, 2020 5:55 pm Leave your thoughtsAuthor(s): Jia Chen, Yue Han, Chun Chen, et al. Abstract: PF228 Session topic: 4. Acute myeloid leukemia –...
ADDITION OF CRENOLANIB TO STANDARD INDUCTION AND CONSOLIDATION THERAPIES IMPROVED LONG-TERM OUTCOMES IN NEWLY DIAGNOSED FLT3-MUTANT AML PATIENTS ≤ 60 YEARS OLD
13 októbra, 2020 5:55 pm Leave your thoughtsAuthor(s): Roland B. Walter, Robert H. Collins, Richard M. Stone, et al. Abstract: PF227 Session topic: 4. Acute...
Liečba akútnej myeloblastovej
13 októbra, 2020 5:55 pm Leave your thoughtsLiečba akútnej myeloblastovej leukémie sa nachádza v stredobode pozornosti vďaka mohutnému pokroku v poznatkoch o patogenetických mechanizmoch a rýchlom vývoji molekúl/látok/liekov namierených proti za leukémiu...
LONG-TERM SAFETY AND EFFICACY OF RITUXIMAB IN 248 ADULT IMMUNE THROMBOCYTOPENIA PATIENTS: RESULTS WITH MORE THAN 5 YEARS OF FOLLOW-UP FROM A FRENCH PROSPECTIVE REGISTRY ITP-RITUX
13 októbra, 2020 5:55 pm Leave your thoughtsAuthor(s): Samuel Deshayes, Mehdi Khellaf, Anissa Zarour, et al. Abstract: S141 Session topic: 33. Platelets disorders Background...
COMPARISON OF STANDARD- AND LOW-DOSE RITUXIMAB IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): DATA FROM THE UK ITP REGISTRY
13 októbra, 2020 5:55 pm Leave your thoughtsAuthor(s): Caitlin Gracie, Abbas Zaidi, Umesh Doobaree, et al. Abstract: S139 Session topic: 33. Platelets disorders Background...
FACTORS AFFECTING THROMBOPOIETIN RECEPTOR AGONIST REINITIATION AFTER DISCONTINUATION IN WELL-CONTROLLED PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN THE UK: RESULTS FROM A MODIFIED DELPHI CONSENSUS PANEL
13 októbra, 2020 5:55 pm Leave your thoughtsAuthor(s): Nichola Cooper, Quentin Hill, John Grainger, et al. Abstract: PS1411 Session topic: 33. Platelets disorders Background...